Prime Vitality dba Prime Peptides: the FDA Record, Dated
Updated August 25, 2026
Prime Vitality, Inc., doing business as Prime Peptides at primepeptides.co from a Santa Barbara, California address, received FDA warning letter 695156-12102024 on December 10, 2024, addressed to Curtis Miller. The letter drew evidence from the company's website, three social platforms, a video, reposted customer reviews, and an on-domain blog post. Its outcome remains unknown.
Entity record
| Entity name, as addressed | Prime Vitality, Inc. dba Prime Peptides |
|---|---|
| Named recipient | Curtis Miller |
| Address on the letter | 735 State St Ste 422, Santa Barbara CA 93101 |
| Storefront | primepeptides.co |
| Letter number | 695156-12102024 |
| Letter date | December 10, 2024 |
| Observation window | Site review conducted October 2024 |
| Batch | One of four same-day letters — see the December 2024 batch record |
Letter mechanics, from the fetched text
| Delivery | Sent by email |
|---|---|
| Response demand | Written reply within 15 working days, directed to FDAADVISORY@fda.hhs.gov |
| Escalation wording | "Seizure and injunction" named among the actions available without further notice |
| Public posting | One week after issuance; content-current date December 17, 2024 |
| Signatory | /S/ Tina Smith, M.S., Captain, USPHS, Director, Office of Unapproved Drugs and Labeling Compliance, Office of Compliance, CDER |
| Statutes cited | FDCA §201(g)(1), 21 U.S.C. 321(g)(1); §201(p), 321(p); §301(d), 331(d); §505(a), 355(a); 21 CFR 201.128 |
Every legal characterization in this record is FDA's, as stated in the letter.
The widest evidentiary sweep in its batch
Of the four December 2024 letters, this one assembles intended-use evidence from the most surfaces. Facebook, Instagram, and YouTube were each reviewed under the agency's attribution formula — each property, the letter reasons, "directs consumers to your … website to purchase" the products — and three distinct evidence categories appear alongside the product catalog:
| Category, described abstractly | What the letter did with it | Method record |
|---|---|---|
| Video content | A ranked-countdown video on the company's YouTube channel was reviewed; both its on-screen text and its spoken narration were transcribed and quoted as labeling evidence | Video evidence record |
| Amplified customer reviews | Reposted customer reviews carrying outcome claims — together with the company's own replies and its professional-endorsement framing — were quoted as the vendor's own intended-use evidence | Amplified-review record |
| On-domain blog post | A listicle-style post with pros-and-statistics framing was quoted exactly as product labeling would be | Blog-as-labeling record |
This index does not reproduce the quoted claims themselves; the categories are what the record documents. The letter's full content, including the compound class it names, is kept at the Prime Peptides letter page.
Outcome status: unknown
As of this page's dateline, no close-out letter or follow-on action tied to letter 695156-12102024 has been located in the public record, and nothing captured by this index documents whether a response was filed within the 15-working-day window. Both points are recorded as unknown. Prime Peptides holds an entry in the vendor index; readers comparing it with the similarly named April 2026 recipient should see Prime Peptides vs Prime Sciences.
Sources
- FDA Warning Letter, Prime Vitality, Inc. dba Prime Peptides, 695156-12102024. fda.gov
- FDA Warning Letters index — search "Prime Vitality" or letter number 695156-12102024 for the original document.
- FDA Roundup, December 17, 2024 — agency summary of the four-letter batch (fda.gov).
Further reading
- 2024 enforcement timeline — the letter in the year's dated sequence.
How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.